SCI Abstract

search
+
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap
In recent years, a small number of people with rare diseases caused by unique genetic variants have been treated with ther...
Antimalarial drug hits cardiac fibrosis
Antimalarial drug hits cardiac fibrosis
Discover the world’s best science and medicine | Nature.com
Lundbeck pays US$2.6 billion for Longboard and its lead epilepsy drug
Discover the world’s best science and medicine | Nature.com
JAK inhibition combats adverse skin reaction
JAK inhibition combats adverse skin reaction
Discover the world’s best science and medicine | Nature.com
Benchmarking recruitment rates for phase III trials
Benchmarking recruitment rates for phase III trials
Discover the world’s best science and medicine | Nature.com
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
The DNA damage response (DDR) is a network of proteins that coordinate DNA repair and cell-cycle checkpoints to prevent da...
FDA approves l-amino acid decarboxylase deficiency gene therapy
Discover the world’s best science and medicine | Nature.com
Senescence as a therapeutic target in cancer and age-related diseases
Senescence as a therapeutic target in cancer and age-related diseases
Cellular senescence is a stress response that restrains the growth of aged, damaged or abnormal cells. Thus, senescence ha...
Chinese innovative drug R&D trends in 2024
Chinese innovative drug R&D trends in 2024
Discover the world’s best science and medicine | Nature.com
Comprehensive measurement of biopharmaceutical R&D investment
Comprehensive measurement of biopharmaceutical R&D investment
Discover the world’s best science and medicine | Nature.com
The breast cancer drug market
The breast cancer drug market
Discover the world’s best science and medicine | Nature.com
A golden age of muscarinic acetylcholine receptor modulation in neurological diseases
A golden age of muscarinic acetylcholine receptor modulation in neurological diseases
Over the past 40 years, the muscarinic acetylcholine receptor family, particularly the M1-receptor and M4-receptor subtype...
FDA approves first complement factor D inhibitor
Discover the world’s best science and medicine | Nature.com
Small molecule improves muscle function in myasthenia gravis
Small molecule improves muscle function in myasthenia gravis
Discover the world’s best science and medicine | Nature.com
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy
Discover the world’s best science and medicine | Nature.com
FDA new drug approvals in Q1 2024
Discover the world’s best science and medicine | Nature.com
Targeting immunogenic cell stress and death for cancer therapy
Targeting immunogenic cell stress and death for cancer therapy
Immunogenic cell death (ICD), which results from insufficient cellular adaptation to specific stressors, occupies a centra...
The antibody–drug conjugate landscape
The antibody–drug conjugate landscape
Discover the world’s best science and medicine | Nature.com
Three-step cures for autoimmune diseases?
Three-step cures for autoimmune diseases?
Robert Plenge, head of Research at Bristol Myers Squibb, discusses his vision of sequential immunotherapy for autoimmune d...
RNA-editing drugs advance into clinical trials
RNA-editing drugs advance into clinical trials
ADAR-based editors that can change the mRNA code offer new opportunities in both rare genetic diseases and common complex ...
Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR
Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR
Quantitative structure–activity relationship (QSAR) modelling, an approach that was introduced 60 years ago, is wide...
Extracellular targeted protein degradation: an emerging modality for drug discovery
Extracellular targeted protein degradation: an emerging modality for drug discovery
Targeted protein degradation (TPD) has emerged in the past decade as a major new drug modality to remove intracellular pro...
Top product forecasts for 2024
Discover the world’s best science and medicine | Nature.com
Upcoming market catalysts in Q1 2024
Upcoming market catalysts in Q1 2024
Discover the world’s best science and medicine | Nature.com
FDA approves first chikungunya vaccine
Discover the world’s best science and medicine | Nature.com
PROTAC in clinic for autoimmune skin disease
PROTAC in clinic for autoimmune skin disease
Discover the world’s best science and medicine | Nature.com
Gene therapy zeroes in on Parkinson disease brain circuits
Gene therapy zeroes in on Parkinson disease brain circuits
Discover the world’s best science and medicine | Nature.com
FDA approves first-in-class AKT inhibitor
Discover the world’s best science and medicine | Nature.com
A decade of HCV drugs
A decade of HCV drugs
Discover the world’s best science and medicine | Nature.com
Antibodies achieve leptin balancing act
Antibodies achieve leptin balancing act
Discover the world’s best science and medicine | Nature.com
Load More
format_indent_increase